Test Confirms Presence of Human T-Cell Lymphotropic Virus-I/II Antibodies

The Human T-cell Lymphotropic viruses (HTLV) are a group of human retroviruses known to cause diseases such as adult T-cell leukemia/lymphoma which is a rare form of blood cancer and inflammation of the nerves in the spinal cord, known as myelopathy, as well as other conditions such as uveitis, and infectious dermatitis.

HTLV can be transmitted from person to person through breastfeeding, unprotected sexual contact, or transfusion of blood from an infected donor. The US Food and Drug Administration (FDA; Silver Springs, MD, USA) which has approved the test require that donated blood be tested for HTLV-I/II antibodies. Currently there are two FDA-licensed screening tests for HTLV-I/II. If the test is positive, the donation is discarded and the donor is notified of his or her deferral.

The MP Diagnostics HTLV Blot 2.4 (MP Biomedicals Asia Pacific Pte Ltd.; Singapore), is a qualitative enzyme immunoassay test, that provides blood establishments with additional information to convey to the donor; specifically, the test can confirm HTLV infection and determine which virus type is causing the infection, HTLV-I or HTLV-II. Many people who are infected with HTLV are unaware of the infection because the virus may not cause any symptoms or signs of infection. Additionally, many people infected with HTLV-I or HTLV-II may never develop any disease caused by the viruses. However, these asymptomatic carriers can still transmit the viruses to others.

Karen Midthun, MD, director of FDA's Center for Biologics Evaluation and Research, said, “The approval of MP Diagnostics HTLV Blot 2.4 will help blood establishments better counsel donors who have had positive results on an FDA-licensed HTLV-I/II screening test.”

Related Links:
US Food and Drug Administration 
MP Biomedicals Asia Pacific Pte Ltd.